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Abstract  
 
Melatonin (MLT) is a well-known free-radical scavenger, involved in the prevention of cellular 
damage that can lead to cancer, aging, and a variety of neurodegenerative diseases. Research on MLT-
related compounds has been required to optimise the maximum pharmaceutical activity with the 
lowest side effects. In our ongoing research we have synthesized new indole-based MLT analogues as 
potential antioxidant agents by modifying the MLT molecule. In this study we build on previous 
findings, through the synthesis, characterization and in vitro antioxidant profiling of a series of new 
indole-based MLT analogues which possess triazole, thiadiazole and carbothioamides on the 3rd 
position on the indole ring. In vitro antioxidant activity was investigated by evaluating their reducing 
effect against oxidation of a redox sensitive fluorescent probe and their radical scavenging activity was 
assessed via the DPPH assay. In addition, in vitro cytotoxic effects of newly synthesized compounds 
were investigated in CHO-K1 cells using the MTT assay.  
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1. Introduction 
 
       Reactive oxygen species (ROS), and reactive nitrogen species (RNS), are products of cellular 
metabolism, and are well known for having both a harmful and beneficial role [1, 2]. Overproduction 
of reactive species causes oxidative stress [3] which may lead to serious damage to vital cell structures 
like proteins and DNA [4, 5]. Oxidative stress has been associated with various diseases such as 
cancer [6], heart diseases [7], neurological disorders such as Alzheimer’s disease [8], Huntington’s 
disease [9, 10], and aging [11]. MLT is a hormone primarily secreted by the pineal gland along with 
many other parts of the human body [11-13] and has a significant anti-oxidant property [14]. MLT 
(Fig.1) and its metabolites are able to function as endogenous free-radical scavengers and broad-
spectrum antioxidants [15, 16]. In addition, MLT and its derivatives have been shown to exhibit the 
regulation of circadian rhythm and immune functions in many physiological processes and therapeutic 
functions [17, 18]. In recent years, the many physiological properties of MLT have stimulated much 
interest in the development of synthetic compounds possessing the indole ring. In addition MLT is a 
highly lipophilic compound that easily passes through cell membranes to reach intracellular 
compartments, especially mitochondria which are well-known for having high concentrations of ROS. 
Also MLT acts in the fixation of oxidant-antioxidant balance in mitochondria [19, 20]. On the other 
hand MLT has very short half-life in the human body, of approximately one hour in blood following 
oral administration. Therefore the synthesis of MLT analogues with longer half-lives is an interesting 
topic for researchers [20, 21]. 
 
       Recent research has showed that compounds with an indole ring such as indol-3-propionic acid 
[22], indole amine triazole [23] and indolehydrazide/hydrazone derivatives [24, 25], have significant 
antioxidant effects. The indole ring of these compounds is the reactive centre dealing with oxidants 
due to its high resonance stability and low activation energy barrier towards free radical reactions [24, 
26]. In addition to these compounds, there are some studies that demonstrate the antioxidant effect of 
1,2,4-triazoles and 1,3,4-thiadiazoles [27-29]. The triazole molecule is one of the most significant and 
well recognized heterocycles which is a common feature of a selection of natural products as well as 
pharmaceutical agents. Triazoles and their derivatives were investigated in many studies and 
established to be associated with a variety of biological activities like antibacterial [30] antifungals 
[31] antitumor; anti-inflammatory; analgesic [32] and antioxidant [33]. In addition this 1,3,4-
thiadiazoles have also been found to be key group of molecules with biological activity particularly 
antibacterial and antioxidant [34]. The broad spectrum activities of 1,2,4-triazoles derivatives have 
attracted the attention of researchers in recent years. Until now, studies showed that modifications of 
the triazole derivatives have proven highly efficient with better potency and lesser toxicity. Based on 
the above findings it was planed and synthesized some indole derivatives with 1,2,4-triazole and 1,3,4-
thiadiazole with different side chains to improve biological activity of indole derivatives. 
 
        In the present study some modifications were made on the MLT molecule to improve its 
antioxidant effect. The acetylaminoethyl side chain in the 3rd position of the indole ring was removed 
and substituted with hydrazinecarbothioamide, triazole and thiadiazole groups.  As a part of our 
ongoing study thirty-one new compounds were synthesized using four different routes. Synthesis of 
1a-h and 3a-h compounds demonstrated high yield with average of 87%. However synthesis of 4a-g 
and 2a-h compounds showed low yield respectively with 28% and 37%.Biological activity of new 
synthesis compounds was investigated in-vitro. The MTT assay was performed to evaluate their 
cytotoxic profiles, the DCFH-DA(2',7'-Dichlorodihydrofluorescein diacetate) assay was carried 
out for revealing the antioxidant activity of the newly synthesized compounds, and the DPPH(2,2-
diphenyl-1-picrylhydrazyl) Free Radical Scavenging Activity test. All the synthesized compounds 
except those formerly synthesized (2d [35], 2h [36], 3c [36], 3d [36]) were characterized on the basis 
of 1H- and 13C-NMR, mass spectra and elemental analysis. 
 
2. Materials and Methods 
 
       The present study aimed to synthesize, characterize and investigate the potential antioxidant and 
cytotoxic effects of indole-based MLT analogues containing hydrazinecarbothioamide, triazole and 
thiadiazoles as side chains attached to the 3-position of the indole ring. Two parts of the MLT 
molecule were modified to develop new indole-based MLT analogue compounds as show in (Fig.1). 
These modifications were done mainly on the MLT acylamino group (Fig.1). 
 
<<Figure 1>> 
 
These modulations of the lead structures were made at two different points: the methoxy group was 
replaced with hydrogen at the 5-position of the indole ring as modification 1 and the acetylaminoethyl 
side chain was replaced by hydrazinecarbothioamide (1a-h), thiadiazole (2a-h) and triazole (3a-3h) 
groups as modification 2. Finally S-alkylation on the compounds (3a-h) provided analogues (4a-g) 
(Table 1). These modifications resulted in a new series of compounds having different heterocyclic 
groups as side chain in the indole nucleus. These modifications helped to investigate the effect of 
substituents with different electronic and lipophilic properties of heterocyclic groups on the 
antioxidant activity and biological half-life of new indole derivatives. Synthetic routes to new MLT 
analogues are outlined in Scheme 1. Reaction of indole 3-methylhydrazine with isothiocyanates in 
ethanol under reflux gave the corresponding hydrazinecarbothioamides (1a-h) in high yields. 
Treatment of 1a-h under strongly acidic conditions proceeded with full regiochemical control to gives 
the corresponding 2-aminothiadiazoles (2a-h), albeit in low to moderate yields. Conversely, treatment 
of 1a-h under basic conditions (aq. NaOH) with heating produced the 2-thiotriazoles (3a-h) in high 
yields with full control of cyclisation regiochemistry. Triazoles (3a-h) could be further alkylated under 
basic conditions to produce substituted triazole 4a-g in low to moderate yield.  
 
<< Scheme 1>> 
 
<< Table 1>> 
 
2.1. Chemistry - Experimental 
 
       Uncorrected melting points were determined with a Büchi melting point B-540 apparatus. The 1H 
and 13C NMR spectra were measured with a Varian 400 MHz instrument using TMS as internal 
standard and DMSO-d6 as solvent. ESI Mass spectra were determined on a Waters Micromass ZQ. 
Elemental analyses were performed using a CHNS-932 instrument (LECO). All spectral analysis was 
performed at Central Laboratory of the Faculty of Pharmacy, Ankara University. Chromatography was 
carried out using Merck silica gel 60 (230–400 mesh ASTM). The chemical reagents used in synthesis 
were purchased from Sigma (Germany) and Aldrich (USA). 
2.1.1. General procedure for the synthesis of hydrazinecarbothioamide compounds 1a-h 
       Equal amounts of 2-(1H-indol-3-yl) acetohydrazide (5 mmol) and aryl or alkylisothiocyanates (5 
mmol) were dissolved in absolute ethanol (20 ml). The mixture was heated under reflux for 4-5 h at 
80-85 ˚C. After completion of the reaction, the reaction mixture was concentrated on the rotary 
evaporator under reduced pressure and kept overnight at room temperature. The crystals thus obtained 
were purified by washing with petroleum ether [35]. 
 
2-(2-(1H-Indol-3-yl)acetyl)-N-ethylhydrazincarbothioamide (1a) 
Yield 95%, m.p. 132 ˚C; 1H-NMR: δ 1.01 (t, 3H, J=7.6 Hz, CH3); 3.42 (q2H, CH2); 3.55 (s, 2H,Ar-
CH2); 6.96 (m, 1H, H-5); 7.05 (m, 1H, H-6); 7.21 (d, 1H, J=2.4 Hz, H-2); 7.32 (d, 1H, J=8 Hz, H-7); 
7.55 (d, 1H, J=7.6 Hz, H-4); 7.78, 9.16, 9.84, 10.88 (s, 4H, NH-NH-CS-NH and NH indole); 13C-
NMR: δ 14.87, 31.07, 38.85, 108.44, 110.00, 111.73, 118.76, 119.19, 121.42, 124.38, 127.65, 136.46, 
170.84 (C=O); ESI MS m/z 277 (M+H, 100%); Anal. calcd. for C13H16N4OS: C, 55.59%; H, 5.92%; 
N, 19.95%. Found: C, 55.21%; H, 6.24%; N, 19.66%. 
2-(2-(1H-Indol-3-yl)acetyl)-N-propylhydrazincarbothioamide (1b) 
Yield 86%, m.p. 143.5 ˚C; 1H-NMR: δ 0.80 (t, 3H, J=7.2 Hz, CH3); 1.46 (m, 2H, CH2); 3.37 (t, 2H, 
J=7.6 Hz, NH-CH2); 3.57 (s, 2H, COCH2); 6.98 (t, 1H, J=7.6 Hz, H-5); 7.07 (t, 1H, J=8.4 Hz, H-6); 
7.23 (d, 1H, J=2.4 Hz, H-2); 7.34 (d, 1H, J=8 Hz, H-7); 7.57 (d, 1H, J=7.6 Hz, H-4); 7.75; 9.18; 9.87; 
10.90; (s, 4H, NH-NH-CS-NH and NH-indole); 13C-NMR: δ 11.60, 22.40, 31.10 45.72 (NH-C); 
108.46, 111.75, 118.77, 119.19, 121.44, 124.40, 127.65, 136.49, 170.86 (C=O), 175.28 (C=S); ESI 
MS m/z 291 (M+H, 100%); Anal. calcd. for C14H18N4OS: C, 57.91%; H, 6.24%; N, 19.29%. Found: 
C, 58.19%; H, 6.75%; N, 19.14%. 
2-(2-(1H-Indol-3-yl)acetyl)-N-benzylhydrazincarbothioamide (1c) 
Yield 78%, m.p. 142.5 ˚C; 1H-NMR: δ 3.58 (s, 2H, COCH2); 4.74 (d, 2H, J=5.6 Hz, benzyl-CH2); 
6.96 (m, 1H, H-5); 7.06 (m, 1H, H-6); 7.23 (d, 1H, J=2.4 Hz, H-2); 7.21-7.35 (m, 6H, Ar-H); 7.56 (d, 
1H, J=8 Hz, H-4); 8.44, 9.35, 9.94, 10.88 (s, 4H, NH-NH-CS-NH and NH-indole); 13C-NMR: δ 30.50; 
46.54 (NH-C); 107.84; 111.15; 118.17; 118.68; 120.84; 123.80; 126.50; 126.88, 127.15, 127.94, 
135.91, 139.20, 170.36 (C=O) C=S?; ESI MS m/z 339 (M+H, 100%); Anal. calcd. for C18H18N4OS: C, 
62.55%; H, 5.49; N, 16.21%.  Found: C, 63.07%; H, 6.01%; N, 16.68%. 
2-(2-(1H-Indol-3-yl)acetyl)-N-phenylhydrazincarbothioamide (1d) 
Yield 90%, m.p. 178.5 ˚C; 1H-NMR: δ 3.63 (s, 2H, COCH2); 6.98 (m, 1H, H-5); 7.07 (m, 1H, H-6); 
7.26 (d, 1H, J=2.4 Hz, H-2); 7.60 (d,1H, J=7.6, H-4); 7.14-7.41 (m, 6H, Ar-H); 9.54, 9.64, 10.11, 
10.91 (s, 4H, NH-NH-CS-NH and NH indole); 13C-NMR: δ 31.17, 108.45, 110.00, 111.75, 118.80, 
119.27, 121.44, 124.45, 125.44, 126.04, 127.71, 128.55, 136.50, 139.57, 167.71, 171.01 (C=O), 
181.33 (S=C); ESI MS m/z 325 (M+H, 100%); Anal. calcd. for C17H16N4OS: C, 62.94%; H, 4.97%; N, 
17.27%. Found: C, 63.05%; H, 5.33%; N, 17.05%. 
2-(2-(1H-Indol-3-yl)acetyl)-N-(2,4-difluorophenyl)hydrazincarbothioamide (1e) 
Yield 81%, m.p. 169 ˚C; 1H-NMR: δ 3.64 (s, 2H, Ar-CH2); 6.98-7.61 (m, 8H, Ar-H); 9.60 (s, 1H, NH 
indole); ESI MS m/z 361 (M+H, %100); Anal. calcd. for C17H14F2N4OS: C, 56.66%, H, 3.92%, N, 
15.55%. Found: C, 56.68%, H, 4.14%, N, 15.66%. 
2-(2-(1H-İndol-3-yl)acetyl)-N-(3-fluorophenyl)hydrazincarbothioamide (1f) 
Yield 92%, m.p. 183.5 ˚C; 1H-NMR: δ  3.63 (s, 2H, COCH2); 6.97 (t, 1H, J=6.8 Hz, H-5); 7.07 (t, 1H, 
J=7.2 Hz, H-6); 7.23-7.61 (m, 7H, Ar-H); 9.60, 9.78, 10.13, 10.90, (s, 4H, NH-NH-CS-NH and NH 
indole); 13C-NMR: δ 31.15, 108.38, 111.76, 118.75, 119.25, 121.41, 124.46, 127.68, 130.10, 136.50, 
141.33, 141.44, 160;76, 163.15, 164.568, 165.87, 167.30, 168.76, 170.22 (C=O); 175.49, 
181.17(C=S); ESI MS m/z 343 (M+H, 100%); Anal. calcd. for C17H15FN4OS: C, 59.63%; H, 4.42%; 
N, 16.36%. Found: C, 59.91%; H, 4.51%; N, 16.51%. 
2-(2-(1H-İndol-3-yl)acetyl)-N-(2,4-dichlorophenyl)hydrazincarbothioamide (1g): 
Yield 91%, m.p. 172.5 ˚C; 1H-NMR: δ 3.62 (s, 2H, COCH2); 6.97 (t, 1H, j=7.2 Hz, H-5); 7.07 (t, 1H, 
J=6.8 Hz, H-6); 7.59 (d, 1H, J=8 Hz, H-4); 7.25-7.68 (m, 5H, Ar-H); 9.47, 9.87, 10.20, 10.90 (s, 4H, 
NH-NH-CS-NH and NH indole); 13C-NMR: δ 31.01, 108.31, 111.71, 118.72, 119.29, 121.41, 124.45, 
127.73, 129.23, 132.34, 136.46, 171.07 (C=O); 182.14 (C=S); ESI MS m/z (M+, 100%); 395  (M+2, 
85%); 397 (M+4, 38%); Anal. calcd. for C17H14Cl2N4OS: C, 51.92%; H, 3.59%; N, 14.25%. Found: C, 
52.30%; H, 3.92%; N, 14.51%. 
2-(2-(1H-Indol-3-yl)acetyl)-N-(3-chlorophenyl)hydrazincarbothioamide (1h): 
Yield 84%, m.p. 168 ˚C; 1H-NMR: δ 3.64 (s, 2H, COCH2); 6.98 (t, 1H, J=6.8 Hz, H-5); 7.07 (t, 1H, 
J=7.2 Hz, H-6); 7.21 (d, 1H, J=7.2 Hz, H-2); 7.60 (d, 1H, J=1.6 Hz, H-4); 7.26-7.44 (m, 5H, Ar-H); 
9.63, 9.81, 10.13, 10.91 (s, 4H, NH-NH-CS-NH and NH indole); 13C-NMR: δ 25.81, 31.15, 108.35, 
111.74, 118.78, 119.24, 121.44, 124.45, 125.18, 127.68, 130.13, 136.49, 141.12, ESI MS m/z 359.5 
(M+H, 72%), 361 (M+H+2, 28%); Anal. calcd. for C17H15N4SOCl: C, 56.90%; H, 4.21%; H, 15.61%. 
Found: C, 57.26%; H, 4.41%; N, 15.31%. 
 
2.1.2. General procedure for the synthesis of compounds 2a-h 
Conc. sulfuric acid (3 ml) was placed in a conical flask, and 2-(1H-Indol-3-yl-acetyl)-N-(aryl or 
alkyl)hydrazincarbothioamide (1 mmol) was added in small portions over a period of 2 h under 
stirring while maintaining the temperature at 0–5 °C. When the reaction was completed the mixture 
was poured into crushed ice and neutralized with 2N NH4OH dropwise until the pH was adjusted to 7.  
The formed precipitate was filtered, washed with water, dried at room temperature and recrystallised 
from absolute ethanol [35]. 
 
5-((1H-Indol-3-yl)methyl)-2-ethylamino-1,3,4-thiadiazole (2a):  
Yield 42%, m.p. 125 ˚C; 1H-NMR: δ 1.12 (t, 3H, J=6.8 Hz, CH3); 3.21 (q, 2H, CH2); 4.26 (s, 2H, Ar-
CH2);6.98 (m, 1H, H-5); 7.09 (m, 1H, H-6); 7.30 (d, 1H, J=2.4, H-2); 7.36 (d, 1H, J=8 Hz, H-7); 7.46 
(d, 1H, J=8 Hz, H-4); 7.73 (s, 1H, NH); 11.01 (s, 1H, NH indole); 13C-NMR: δ 14.62, 26.51, 
39.31(NH-C); 110.94, 112.02, 118.76, 119.11, 121.73, 124.25, 126.99, 136.75, 159.29, 168.89 (S-C-
N); ESI MS m/z 259 (M+H, 100%), 300 (M+H+CH3CN, 76%); Anal. calcd. for C13H14N4S: C, 
57.43%, H, 5.75%, N, 20.61%. Found: C, 57.55%, H, 5.66%, N, 20.23%. 
5-((1H-Indol-3-yl)methyl)-2-propylamino-1,3,4-thiadiazole (2b): 
Yield 44%, m.p. 148 ˚C; 1H-NMR: δ 0,86 (t, 3H, J=7.6 Hz, CH3); 1.52 (m, 2H, CH2); 3.15 (q, 2H, 
NH-CH2); 4.26 (s, 2H, Ar-CH2); 6.98 (t, 1H, J=8 Hz, H-5); 7.09 (t, 1H, J=8 Hz, H-6); 7.31 (d, 1H, 
J=2.4 Hz, H-2); 7.36 (d, 1H, J=8 Hz, H-7); 7.46 (d, 1H, J=8.4 Hz, H-4); 7,82 (s, 1H, NH ); 11.00 (s, 
1H, NH-indole); 13C-NMR: δ 11.78, 22.16, 26.51, 47.05 (NH-C); 110.91, 112.03, 118.77, 119.12, 
121.74, 124.29, 127.01, 136.76, 159.22, 169.06 (N-C-S); ESI MS m/z (M+H, 100%), 314 
(M+H+CH3CN, 100%); Anal. calcd. for C14H16N4S: C, 51.51%; H, 6.79%; N, 17.16%. Found: C, 
51.23%; H, 5.57%; N, 16.78%. 
5-((1H-Indol-3-yl)methyl)-2-amino-1,3,4-thiadiazole (2c): 
Yield 39%, m.p. 177 ˚C; 1H-NMR: δ 4.22 (s, 2H, Ar-CH2); 6.94 (bs, 2H, NH2); 6.97 (dt, 1H, J1=8.4, 
J2=1.2 Hz, H-5); 7.07 (dt, 1H, J1=8.4, J2=1.2 Hz H-6); 7.27 (d,1H, J=2.4 Hz, H-2); 7.35 (d, 1H, J=8 
Hz, H-7); 7.45 (d, 1H, J=8 Hz, H-4); 10.97 (s, 1H, NH-indole); 13C-NMR: δ 25.98; 110.98; 111.42; 
118.24; 118.48; 121.11; 123.52; 126.47; 136.18; 159.21; 168.41 (N-C-S); ESI MS m/z (M+H, 37%), 
272 (M+H+CH3CN, 100%); Anal. calcd. for C11H10N4S: C, 55.21%, H, 4.63%, N, 23.41%. Found: C, 
54.90%, H, 4.58%, N, 23.35%. 
5-((1H-Indol-3-yl)methyl)-2-(2,4-difluorophenyl)amino-1,3,4-thiadiazole (2e):  
Yield 26%, m.p. 141˚C; 1H-NMR: δ 4.34 (s, 2H, Ar-CH2); 6.70-8.33 (m,8H, Ar-H); 9.89 (s, 1H, NH); 
11.01 (s,1H, NH indole); ESI MS m/z 343 ( M+H, 100%), 384 (M+H+CH3CN, 44%); Anal. calcd. for 
C17H12 F2N4S: C, 58.11%, H, 3.73%, N, 15.94%. Found: C, 57.98%, H, 3.63%, N, 15.80%. 
5-((1H-Indol-3-yl)methyl)-2-(3-fluorophenyl)amino-1,3,4-thiadiazole (2f): 
Yield 22%, m.p. 183˚C; 1H-NMR: δ 4.36 (s, 2H, Ar-CH2); 6.73-7.63 (m, 9H, Ar-H); 10.36 (s, 1H, 
NH); 11.01 (s, 1H, NH indole); 13C-NMR: δ 26.36; 104.38; 104.64; 108.28; 110.94; 112.06; 113.51; 
118.76; 119.18; 121.77; 124.34; 126.97; 131.02; 136.77; 124.75; 161.88; 164.25 (S-C-N); ESI MS 
m/z 325 (M+H, 100%), 366 (M+H+CH3CN, 33%); Anal. calcd. for C17H13FN4S: C, 61.24%, H, 
4.23%, N, 16.81%. Found: C, 61.16%, H, 4.07%, N, 16.69%. 
5-((1H-Indol-3-yl)methyl)-2-(2,4-Dichlorophenyl)amino-1,3,4-thiadiazole (2g): 
Yield 50%, m.p. 112˚C; 1H-NMR: δ 4.35 (s, 2H, Ar-CH2); 6.97 (m, 1H, H-5); 7.07 (m, 1H, H-6); 7.39 
(d, 1H, J=2.4 Hz, H-7); 7.48 (d, 1H, J=7.6 Hz, H-4); 7.21-7.59 (m, 4H, Ar-H); 8.33 (d, 1H, J=9.2 Hz, 
NH); 11.02 (s, 1H, NH indole);13C-NMR: δ 25.78; 110.38; 111.51; 118.22; 118.61; 121.21; 121.89; 
122.74; 123.81; 126.08; 126.38; 127.74; 128.76; 136.21; 136.48; 162.66; 164.11 (S-C-N); ESI MS 
m/z 375  (M+, 100%), 377 (M+2, 68%), 379 (M+4, 13%), 416 (M++CH3CN, 77%); Anal. calcd. for 
C17H12Cl2N4S: C, 49.43%, H, 3.95%, N, 13.56%. Found: C, 49.03%, H, 3.54%, N, 14.03%. 
 
2.1.3. General procedure for the synthesis of compounds 3a-h 
       2-(1H-Indol-3-yl-acetyl)-N-(aryl or alkyl)hydrazincarbothioamide (2 mmol) and 2N NaOH 
solution (25 ml) were placed in conical flask. The mixture was heated under reflux for 4-5 h. After 
completion of the reaction, the reaction mixture was neutralized with 2N HCl dropwise till pH was 
adjusted to 7. The mixture was kept aside for a few minutes. The precipitate thus obtained was filtered, 
washed with water, and recrystallized from a mixture of ethanol/water (4:1) [35]. 
 5-((1H-Indol-3-yl)methyl)-4-ethyl-4H-1,2,4-triazole-3-thiol (3a): 
Yield 91%, m.p. 191.5˚C; 1H-NMR: δ 0.92 (t, 3H, J=7.6 Hz, CH3); 3.90 (q, 2H, CH2); 4.20 (s, 2H, Ar-
CH2); 6.98 (dt, 1H, J1=7.2, J2=0.8 Hz, H-5); 7.09 (dt, 1H, J1=7.2, J2=1.2 Hz H-6); 7.33 (d, 1H, J=2.4 
Hz, H-2); 7.37 (d, 1H, J=8 Hz, H-7); 7.49 (d, 1H, J=7.6 Hz, H-4); 11.05 (s, 1H, NH indole); 13.54 (s, 
1H, SH); 13C-NMR: δ 13.31; 22.34; 38.72; 107.70; 112.057; 118.73; 119.16; 121.76; 124.61;127.14; 
136.70; 151.70; 166.67(N-C-S); ESI MS m/z 259 (M+H, 100%), 300 (M+H+CH3CN, 8%); Anal. 
calcd. for C13H14N4S: C, 57.63%, H, 5.73%, N, 20.68%.  Found: C, 57.93%, H, 5.96%, N, 20.51%. 
5-((1H-Indol-3-yl)methyl)-4-propyl-4H-1,2,4-triazole-3-thiol (3b): 
Yield 76%, m.p. 151.5˚C; 1H-NMR: δ 0.73 (t, 3H, J=7.6 Hz, CH3); 1.35 (m, 2H, CH2); 3.78 (t, 2H, 
J=7.6 Hz, NH-CH2); 4.19 (s, 2H, Ar-CH2); 6.98 (t, 1H, J=7.2 Hz, H-5); 7.09 (t, 1H, J=7.2 Hz, H-5); 
7.33 (d, 1H, J=2 Hz, H-2); 7.37 (d, 1H, J=8 Hz, H-7); 7.47 (d, 1H, J=7.6 Hz, H-7); 11.047??2 d.p.(s, 
1H, NH indole); 13.54 (s, 1H, SH); 13C-NMR: δ 10.59; 20.51; 21.77; 44.42 (N-C); 107.12; 111.50; 
118.14; 118.58; 121.20; 124.00; 126.57; 136.13; 151.27; 166.40 (N-C-S); ESI MS m/z 273 (M+H, 
100%); Anal. calcd. for C14H16N4S: C, 60.73% H, 6.01%, N, 20.23%. Found: C, 60.25%, H, 5.79%, N, 
19.77%.  
5-((1H-Indol-3-yl)methyl)-4-(2,4-difluorophenyl-4H-1,2,4-triazole-3-thiol (3e): 
Yield 85%, m.p. 242.5˚C; 1H-NMR: δ 3.96 (q, 2H, Ar-CH2); 6.70-7.48 (m, 8H, Ar-H); 10.86 (s, 1H, 
NH indole); 13.85 (s, 1H, SH); ESI MS m/z 343 (M+H, 100%); Anal. calcd. for C17H12 F2N4S: C, 
59.63%, H, 3.53%, N, 16.36%. Found: C, 59.50%, H, 3.77%, N, 16.21%.  
5-((1H-Indol-3-yl)methyl)-4-(3-fluorophenyl)-4H-1,2,4-triazole-3-thiol (3f): 
Yield 94%, m.p. 134˚C; 1H-NMR: δ 3.96 (s, 2H, Ar-CH2); 6.67-7.49 (m, 9H, Ar-H); 10.85 (bs, 1H, 
NH indole); 13C-NMR: δ 22.76; 107.56; 111.84; 116.08; 116.24; 116.32; 116.45; 118.58; 118.89; 
121.51; 124.07; 124.98; 127.04; 130.92; 131.02; 136.28; 136.43; 151.38; 160.98; 163.41; 167.94 (N-
C-S); ESI MS m/z 325 (M+H, 100%); Anal. Calcd. forC17H13FN4S: C, 55.54%, H, 4.88%, N, 15.24%.  
Found: C, 55.03%, H, 3.96%, N, 15.04%.  
5-((1H-Indol-3-yl)methyl)-4-(2,4-dichlorophenyl)-4H-1,2,4-triazole-3-thiol (3g): 
Yield 89%, m.p. 254.5˚C; 1H-NMR: δ 3.91 (q, 2H, Ar-CH2); 6.92 (t, 1H, J=8 Hz, H-5); 7.05 (t, 1H, 
J=8 Hz, H-6); 7.497 (d, 1H, J=6.4 Hz, H-7); 7.52 (d,1H, J=2.4 Hz, H-4); 6.77-7.78 (m, 4H, Ar-H); 
10.91 (s, 1H, NH indole); 13.86 (s, 1H, SH); 13C-NMR: δ 22.01; 105.87; 111.30; 117.80; 118.39; 
120.99; 123.90; 126.52; 128.28; 129.60; 130.13; 132.05; 133.22; 135.23; 135.91; 151.11; 167.735 (N-
C-S); ESI MS m/z 375 ( M+, 100%), 377 (M+2, 58%), 379 (M+4, 13%), 426 (M+CH3CN, 11%); 
Anal. calcd. for C17H12 Cl2N4S: C, 53.76%, H, 3.32%, N, 14.75%. Found: C, 53.57%, H, 3.29%, N, 
14.69%. 
5-((1H-Indol-3-yl)methyl)-4-(3-chlorophenyl)-4H-1,2,4-triazole-3-thiol (3h): 
Yield 83%, m.p. 140˚C; 1H-NMR: δ 3.96 (s, 2H, Ar-CH2); 6.91 (t, 1H, J=7.2 Hz, H-5); 7.028 (t, 1H, 
J=7.6 Hz, H-6); 7.19 (d, 1H, J=7.6 Hz, H-2); 6.71-7.58 (m, 6H, Ar-H); 10.86 (s,1H, NH indole); 13.77 
(s, 1H, SH); 13C-NMR: δ 22.73; 107.03; 111.88; 118.50; 118.97; 121.57; 124.26; 126.99; 127.56; 
128.74; 129.78; 131.09; 133.57; 135.56; 136.43; 151.72;168.14 (S-C-N); ESI MS m/z 341.2 (M+, 
100%); 343.3 (M+2, 30%), 382 (M+CH3CN, 20%); Anal. calcd. for C17H13ClN4S: C, 58.36%, H, 
4.03%, N, 16.01%. Found: C, 58.54%, H, 4.01%, N, 15.70%. 
 
2.1.4. General procedure for the synthesis of compounds 4a-g 
       5-((1H-Indol-3-yl) methyl)-4-(substituted aryl/alkyl)-4H-1,2,4-triazole-3-thiol (1 mmol) was 
dissolved in a solution of 2N KOH (2 ml) and absolute ethanol (20 mL) in a conical flask. R-X (X=Cl) 
(1 mmol) was added in to the mixture and stirred at room temperature for 2-3 h. After completion of 
the reaction, the reaction mixture was poured onto crushed ice. The formed precipitate was filtered, 
washed with water, dried at room temperature and recrystallized from absolute ethanol [33]. 
 
2-(5-((1H-Indol-3-yl)methyl)-4-ethyl-4H-1,2,4-triazole-3-ylthio)-N-phenylacetamide (4a): 
Yield 17%, m.p. 120˚C; 1H-NMR: δ 0.96 (t, 3H, J=6.8 Hz, CH3); 3.91 (q, 2H, CH2); 4.09 (s, 2H, Ar-
CH2); 4.25 (s, 2H, S-CH2-CO); 6.92-7.55 (10H, m, Ar-H); 10.32 (s, 1H, amide-NH); 10.97 (s,1H, NH 
indole); 13C-NMR: δ 14.55; 21.43; 28.90; 37.51; 108.30; 111.37; 118.40; 118.45; 119.01; 121.11; 
123.42; 123.61; 126.65; 128.69; 136.16; 138.66; 148.32; 154.44 (N-C-S); 165.62 (C=O); ESI MS m/z 
392 (M+H, 100%); Anal. calcd. for C21H21N5OS: C, 56.04%, H, 6.15%, N, 15.56%. Found: C, 
55.68%, H, 5.60%, N, 15.22%. 
2-(5-((1H-Indol-3-yl)methyl)-4-propyl-4H-1,2,4-triazole-3-ylthio)-N-propylacetamide (4b): 
Yield 32%, m.p. 79˚C; 1H-NMR: δ 0.71 (t, 3H, CH3); 0.79 (t, 3H, J=7.2 Hz, CH3); 1.34 (m, 2H, CH2); 
1.43 (m, 2H, CH2); 2.97 (q, 2H, CO-NH-CH2); 3.78 (t, 2H, J=7.6, triazole- NH- CH2); 3.82 (s, 2H, Ar-
CH2); 4.23 (s,  2H, S-CH2-CO); 6.94 (t,1H, J=8 Hz, H-5); 7.06 (t,1H, J=8.4 Hz, H-6); 7.25 (d, 1H, J=2 
Hz, H-2); 7.34 (d,1H, J=8.4 Hz, H-7); 7.50 (d, 1H, J=8 Hz, H-4); 8.16 (bs, 1H, amide-NH); 10.960  
(s,1H, NH indole); 13C-NMR: δ 11.08; 11.72; 22.06; 22.59; 22.99; 37.29; 43.12; 45.26; 79.63; 108.95; 
111.90; 118.95; 121.65; 124.07; 127.21; 136.71; 149.14; 155.04; 167.12 ( C=O); ESI MS m/z 372.3 
(M+H, 100%); Anal. calcd. for C19H25N5OS: C, 58.18%, H, 7.02%, N, 17.85%. Found: C, 58.77%, H, 
6.96%, N, 17.13%. 
2-(5-((1H-Indol-3-yl)methyl)-4-benzyl-4H-1,2,4-triazole-3-ylthio)-N-(2-fluorophenyl)acetamide 
(4c): Yield 30%, m.p. 182.5˚C; 1H-NMR: δ 4.13(s, 2H, indole-CH2); 4.20 (s, 2H, benzyl-CH2); 5.18 
(s, 2H, amide-CH2); 6.92-7.88 (m, 14H, Ar-H); 10.16 (s, 1H, amide-NH); 10.91 (s, 1H, NH-indole); 
13C-NMR: δ 22.20; 37.64 (S-C); 47.02 (N-C); 108.48; 111.89; 115.87; 116.07; 118.98; 121.67; 
124.09; 124.25; 124.87; 125.86; 126.27; 126.38; 127.02; 127.22; 128.20; 129.08; 135.832; 136.76; 
149.86; 152.56; 155.00; 155.46; 166.82 (C=O); ESI MS m/z 472.2 (M+H, 100%); Anal. calcd. for 
C26H22 FN5OS: C, 66.22%, H, 4.70%, N, 14.85%. Found: C, 65.73%, H, 5.08% N, 14.36%. 
2-(5-((1H-İndol-3-yl)methyl)-4-phenyl-4H-1,2,4-triazole-3-ylthio)-N-propylacetamide (4d): 
Yield 17%, m.p. 165.5˚C; 1H-NMR: δ 0.89 (t, 3H, j=7.6 Hz, CH3); 1.53 (m, 2H, CH2);  3.20 (q, 2H, 
CO-NH-CH2); 3.73 (s, 2H, Ar-CH2); 4.16 (s, 2H, S-CH2-CO); 6.61-7.50 (m, 10H, Ar -H); 7.96 (bs, 
1H, amide-NH); 8.10 (s,1H, NH indole); 13C-NMR: δ 11.39; 22.05; 22.56; 34.56; 41.56; 109.34; 
110.00; 111.10; 118.78; 119.71; 122.28; 122.69; 126.63; 127.02; 129.78; 130.19;132.72; 136.02; 
152.17; 155.39 (N-C-S); 168.68 (C=O); ESI MS m/z 406 (M+H, 100%); Anal. calcd. for C22H23 
N5OS: C, 64.44%, H, 5.78%, N, 17.08%. Found: C, 64.21%, H, 5.88%, N, 16.85%. 
2-(5-((1H-Indol-3-yl)methyl)-4-(2,4-difluorophenyl)-4H-1,2,4-triazole-3-ylthio)-N-propylacetamide 
(4e): 
Yield 45%, m.p. 140˚C; 1H-NMR: δ0.81 (t, 3H, j=7.6 Hz, CH3); 1.37 (m, 2H, CH2);  2.99 (q, 2H, CO-
NH-CH2); 3.85 (s, 2H, Ar-CH2); 4.08 (s, 2H, S-CH2-CO); 6.69-7.51 (m, 8H, Ar-H); 8.16 (t, 1H, J=5.2 
Hz, amide-NH); 10.81 (s, 1H, NH indole); ESI MS m/z 442 (M+H, 100%); Anal. calcd. for 
C22H21F2N5OS: C, 59.85%, H, 4.79%, N, 15.86%. Found: C, 59.70%, H, 4.97%, N, 15.66%. 
2-(5-((1H-Indol-3-yl)methyl)-4-(3-fluorophenyl)-4H-1,2,4-triazole-3-ylthio)-N-propylacetamide(4f): 
Yield 40%, m.p. 145˚C; 1H-NMR: δ 0.81 (t, 3H, J=7.6 Hz, CH3); 1.37 (m, 2H, CH2); 2.98 (q, 2H, CO-
NH-CH2); 3.84 (s, 2H, Ar-CH2); 4.11 (s, 2H, S-CH2-CO); 6.69-7.55 (m,9H, Ar-H); 8.16 (t, 1H, j=5.2 
Hz, amide-NH); 10.80 (s, 1H, NH indole); 13C-NMR: δ 11.75; 22.025; 22.61; 36.69; 41.16; 108.36; 
111.77; 115.19; 115.43; 117.18; 117.38; 118.63; 118.87; 121.53; 123.84; 124.03; 124.06; 127.02; 
131.66; 131.75; 134.87; 134.97; 136.45; 150.10; 155.134; 161.13; 163.58 (N-C-S); 166.85 (C=O); ESI 
MS m/z 424 ( M+H, 100%); Anal. calcd. for C22H22FN5OS: C, 62.39%, H, 5.24%, N, 16.54%. Found: 
C, 62.32%, H, 5.28%, N, 16.35%.     
2-(5-((1H-Indol-3-yl)methyl)-4-(2,4-dichlorophenyl)-4H-1,2,4-triazole-3-ylthio)-N-
phenylacetamide(4g): 
Yield 15%, m.p. 219˚C; 1H-NMR: δ4.03 (s, 2H, Ar-CH2); 4.12(s, 2H, S-CH2-CO); 6.72-7.80 (m, 13H, 
Ar-H); 10.27 (s,1H, amide-NH); 10.82  (s, 1H, NH indole); 13C-NMR: δ 21.47; 37.30; 107.15; 111.19; 
117.96; 118.28; 118.99; 120.93; 123.43; 123.47; 126.56; 128.51; 128.69; 129.36; 129.76; 131.13; 
132.53; 135.68; 135.90; 138.61; 149.66; 154.80 (N-C-S); 165.26 (C=O); ESI MS m/z 508 (M+, 
100%), 510 (M+2, 75%), 512 (M+4, 16%); Anal. calcd. for C25H19Cl2N5OS: C, 59.06%, H, 3.77%, N, 
13.77%. Found: C, 59.60%, H, 4.27%. N, 13.47%. 
 
2.2 .Experimental - Biological Activity  
 
2.2.1. Cell culture and reagents 
 
CHO-K1 cells were purchased from ATCC and maintained at 37 °C in 5% CO2 atmosphere. 
Dulbecco’s modified Eagle’s medium (DMEM) / F12 (Sigma) (1:1) nutrient mixture medium 
supplemented with 10% foetal bovine serum, 1% of a 100 U/mL penicillin-streptomycin solution, 2 
mM (final concentration) L-glutamine and 1 mM (final concentration) sodium pyruvate was used in all 
cell incubations. Hyclone characterized fetal bovine serum (FBS) is purchased from Thermo 
Scientific. 2′,7′-Dichlorofluorescin diacetate (DCFH-DA), 2,2-Diphenyl-1-picrylhydrazyl (DPPH), 
sodium pyruvate and L-glutamine were obtained from Sigma. 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) was purchased from Invitrogen. Test materials were 
dissolved in dimethyl sulfoxide (DMSO) and the final concentration of DMSO never exceeded 0.1% 
v/v in cell culture medium. 
 
2.2.2. Cytotoxic effects via the MTT assay 
 
       CHO-K1 cells were seeded in 96-well plates (5x103cells/well) and incubated at 37 ˚C in a humid 
atmosphere containing 5% CO2 for 24 h. Cells were treated with the newly synthesized compounds 
(10 µM) for 24 h. Control (medium only), vehicle control and positive control (15 µM Triton X-100) 
were included in every experiment. Following the exposure period the medium was removed, cells 
were washed with phosphate buffered saline(PBS) and then incubated with MTT (1 mg/ml) for 4 h at 
37 °C. MTT solution was removed and formazan crystals were dissolved in DMSO. The absorbance 
was recorded at 550 nm on a microplate reader. The ratio of the absorbance of treated samples to the 
absorbance of control (taken as 100%) was expressed as % cell viability.  
 
2.2.3. Measurement of intracellular ROS (antioxidant activity on ROS-induced DCFH-DA 
oxidation) 
       For estimation of intracellular ROS, DCFH-DA was used as a probe. In cellular systems the non-
fluorescent probe DCFH-DA readily crosses the cell membrane and undergoes hydrolysis by 
intracellular esterases to non-fluorescent 2',7'-dichlorofluorescin (DCFH). In the presence of ROS, 
DCFH is oxidized to highly fluorescent dichlorofluorescein (DCF) [37] which can be detected by a 
fluorescent microplate reader. The DCF fluorescence intensity is believed to be parallel to the amount 
of ROS formed intracellularly. 
       Cells were seeded in black 96-well plates at a density of 5x103 cells/well and incubated at 37˚C in 
a humid atmosphere containing 5% CO2 for 24 h for cell attachment. The medium was removedand 
then cells were incubated with DCFH-DA (20μM) containing medium for 30 minutes. Cells were 
washed with PBS to remove excess DCFH-DA. 10 µM synthesized compounds and 10 µM cumene 
hydroperoxide (CMHP) were added into medium. The production of fluorescent DCF was evaluated 
by monitoring fluorescence intensity at 488 nm excitation, 530 nm emission wavelengths for 60 
minutes. 
2.2.4. DPPH free radical scavenging activity 
The free radical scavenging activities of newly synthesized compounds were tested by their 
ability to bleach the stable radical DPPH [38]. DPPH presents a maximum of absorbance at 515 nm; 
when DPPH reacts with an antioxidant compound, which can donate hydrogen, this absorbance 
diminishes and can be measured on a visible spectrophotometer. 
 
       20 μL of the samples (100 μM) were added to 180 μL of DPPH solution (150 μM) in methanol–
water (80:20, v/v) in 96-well plates, incubated for 30 minutes at room temperature then DPPH 
reduction was estimated at 517 nm. Percentage inhibition by the sample treatment was determined by 
comparison with a DMSO-treated control group. All experiments were carried out in triplicate. MLT 
and BHT were used as a reference compounds. The radical scavenging activities were expressed as the 
inhibition percentage and were calculated using the formula: Radical scavenging activity (%) = [(A0 – 
A1 / A0 ) ×100] Where A0 is the absorbance of the control (blank, without compound) and A1 is the 
absorbance of the compound. 
 
3. Results and Discussion 
 
3.1. Cytotoxic effects of the synthesized compounds 
       The cytotoxic effect of the synthesized compounds in CHO-K1 cells was evaluated by the MTT 
assay (Fig 2). CHO-K1 cells are used because many studies as well as our previous study suggested 
them as a relevant model for in vitro antioxidant screening studies [39]. Furthermore CHO cells are 
advantageous since they have active CYP enzymes that make them a good in vitro model for detecting 
the toxicity of chemicals as well as some of their metabolites without adding S9 fraction. 
<< Figure 2>> 
 
3.2. Antioxidant effects of the synthesized compounds 
 
       The protective effect of newly synthesized MLT analogues against cumene hydroperoxide 
induced DCFH-DA oxidation was determined in CHO-K1 cells that were preloaded with the 
fluorescent probe. Oxidation of the probe that locates in the cytosol was screened at various time 
intervals up to 60 min (Fig 3). Several compounds were found to have antioxidant activity whereas 1b 
and 2e were found to be the most potent two compounds among all. Therefore their reducing activity 
against DCFH oxidation was further investigated at their various concentrations (Fig 4). 
 
<< Figure 3>> 
 
<< Figure 4>> 
 
3.3. DPPH free radical scavenging activity 
       Free radical scavenging activity of the newly synthesized compounds was further investigated in a 
cell free in vitro model where an active radical, DPPH was used. The radical scavenging activity of a 
compound can be detected via decrease in the absorbance of DPPH. As can be seen in (Fig.5) 
compounds which named as 1a-h and 3a-h are more potent radical scavengers then 2 and 4 coded 
compounds. 
<< Figure 5>> 
 
4. Conclusion 
In this study thirty one new indole-based MLT analogues were synthesized and their 
antioxidant and cytotoxic effects were tested by three different assays. The MTT assay was used for 
determining the cytotoxic profiles in CHO-K1 cells, and the DCFH-DA and DPPH assays were 
preformed to reveal the antioxidant activity. According to the results of the MTT assay 1a, 1d, 2b, 2h, 
and 4c (10 µM) showed significant proliferative effect on CHO cells. However other compounds have 
demonstrated cytotoxic effects at their 10 µM concentrations. Compounds with cytotoxic effect can be 
tested for a possible anticancer activity in further studies due to the similarity of chemical structures to 
sunitinib which is a receptor tyrosine kinase inhibitor [40] and was approved by the FDA for the 
treatment of renal cell carcinoma. According to the DCFH-DA assay in the presence of CMHP with 
p<0.05 degree of significance, 1b and 2e were observed with the highest antioxidant effect 
respectively with values of 74% and 81%. This was followed by 1c, 3g, 4d, 1d respectively, with the 
rate of 83%, 88% and 89%. The concentration dependence effect of the most active compounds 1b 
and 2e was investigated against melatonin at the same concentration. Depending on the dose of 1b and 
2e when the concentration is increasing the antioxidant effect is also increasing and this effect is more 
potent than melatonin at concentrations of 1 and 10 µM.  
The DPPH assay is a cell-free in vitro screening test for the radical scavenging activity. 
Among newly synthesized compounds generally hydrazinecarbothioamide (1a-h) and 1,2,4-triazole-
3-thiol (3a-h) derivatives were found to have high scavenging activity whereas (4a-g) derivatives were 
found to have the least scavenging activity. 1b which was found to have the highest antioxidant effect 
in the cell based in vitro DCFH assay was found to have high scavenging activity in DPPH assay too. 
This finding indicates that the antioxidant effect of 1b is probably is a result of its radical scavenging 
activity. However 2e which was also found to have antioxidant activity according to the DCFH assay, 
and was found to have very low scavenging activity in the DPPH assay which suggests an alternative 
mechanism for its antioxidant activity. On the other hand almost all hydrazincarbothioamideand 1,2,4-
triazole-3-thiol derivatives were found to have radical scavenging activity in the DPPH assay where 
no antioxidant activity was observed in the cell based DCFH assay. This result could be the result of 
limited availability of the compounds in cell cytosol because of the possible membrane passage. This 
speculation needs to be further verified experimentally.  
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 Table 1. Chemical structures of new indole-based MLT analogues 
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Figure 1. Modifications on MLT molecule to develop new indole-based analogues 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2: Effect of samples (10µM) on cell viability evaluated by MTT assay. Bars represent ‘medium 
± standard deviation’ values from five individual experiments. *p<0.05, ** p<0.005, *** p<0.0005, 
compared to vehicle control group. TritonX-100 used as positive control group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3: DCFH oxidation in CHO cells after 60 minutes incubation with compounds (10 µM) in the 
presence of cumene hydroperoxide (CMHP). Bars represent ‘medium ± standard deviation’ values 
obtained from five individual experiments. Statistical comparisons of samples with CMHP were 
compared to CMHP alone control group. *p<0.05, ** p<0.005, *** p<0.0005 (AA: ascorbic acid) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4: DCFH oxidation in CHO cells after 60 minutes incubation with MLT, compounds 1b and 2e 
in the presence of cumene hydroperoxide(CMHP). Bars represent ‘medium ± standard deviation’ 
values from five individual experiments. The values above the bars represent percentage of the 
absorbance values comparing with CMHP group used as control. All the statistical analysis of samples 
with CMHP was performed by comparing to the CMHP alone group. *p<0.05, ** p<0.005, *** 
p<0.0005 (MLT: melatonin) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5: Radical scavenging activity of compounds (100 µM) determined by DPPH assay. Bars 
represent ‘medium ± standard deviation’ values from four different experiments. BHT and MLT were 
used as reference (BHT: Butylated hydroxytoluene, MLT: Melatonin). 
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Scheme 1. Synthetic route to obtain new indole-based melatonin analogue compounds 
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